Sudeep Pharma peers

Companies like Sudeep Pharmalatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals
₹ CrorePeersSUDARSCHEMSTYRENIXSHARDACROPREFEXRCFRALLISRAINPRIVISCLMcap ₹12,764 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SUDEEPPHRM
FY26
SUDARSCHEM
FY26
STYRENIX
FY26
SHARDACROP
FY26
Peer
Average
Valuation — at last close
P/E72.91×386.07×17.42×◆ 9.04×137.51× -47%
P/B14.45×2.46×2.33×◆ 1.96×2.25× +542%
EV/EBITDA57.74×16.29×9.72×◆ 5.18×10.40× +455%
Market Cap₹12,764 Cr₹8,486 Cr₹3,187 Cr₹6,156 Cr₹5,943 Cr +115%
Growth
Revenue CAGR 3Y—◆ 62.01%13.17%9.20%28.13%
Revenue CAGR 5Y—◆ 39.33%16.08%17.07%24.16%
Net Income CAGR 3Y—-3.05%-0.03%◆ 25.81%7.58%
Revenue YoY (latest Q)20.92%5.39%◆ 24.36%13.19%14.31% +46%
Net Income YoY (latest Q)10.76%◆ 88.00%-48.19%23.36%21.06% -49%
Profitability
EBITDA Margin◆ 34.55%6.03%9.98%20.43%12.15% +184%
Net Income Margin◆ 27.14%0.42%5.32%12.93%6.22% +336%
Return on Common Equity19.57%0.65%14.43%◆ 24.16%13.08% +50%
Return on Capital Employed21.29%3.56%12.97%◆ 24.51%13.68% +56%
Return on Assets◆ 14.83%0.42%7.66%12.96%7.01% +111%
Credit & Quality
Total Debt/Equity0.17×0.55×0.23×◆ 0.00×0.26× -35%
Interest Coverage27.23×1.47×11.78×◆ 427.86×147.04× -81%
Scale — latest FY
Revenue / Total Income₹642 Cr₹9,787 Cr₹3,438 Cr₹5,268 Cr₹6,164 Cr -90%
Net Income₹174 Cr₹40.8 Cr₹183 Cr₹681 Cr₹302 Cr -42%
Total Assets₹1,175 Cr₹9,723 Cr₹2,483 Cr₹5,780 Cr₹5,995 Cr -80%
EPS₹15.5₹2.8₹103.98₹75.47₹60.75 -74%
Book Value per Share₹78.21₹439.52₹776.75₹347.65₹521.31 -85%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.